Mitchell, N. M., Taylor, A. O., Chang, C. H., Bystrom, R., de Castro, C., Erba, H., … LeBlanc, T. (2025). Real-world survival outcomes with first-line venetoclax therapy in AML. In Blood (Vol. 146, pp. 1660–1660). American Society of Hematology. https://doi.org/10.1182/blood-2025-1660

Mitchell, Nia M., Allison O. Taylor, Cheryl H. Chang, Rebecca Bystrom, Carlos de Castro, Harry Erba, Sanghee Hong, et al. “Real-world survival outcomes with first-line venetoclax therapy in AML.” In Blood, 146:1660–1660. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-1660.

Mitchell NM, Taylor AO, Chang CH, Bystrom R, de Castro C, Erba H, et al. Real-world survival outcomes with first-line venetoclax therapy in AML. In: Blood. American Society of Hematology; 2025. p. 1660–1660.

Mitchell, Nia M., et al. “Real-world survival outcomes with first-line venetoclax therapy in AML.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 1660–1660. Crossref, doi:10.1182/blood-2025-1660.

Mitchell NM, Taylor AO, Chang CH, Bystrom R, de Castro C, Erba H, Hong S, Lin C, Wolf S, Locke SC, LeBlanc T. Real-world survival outcomes with first-line venetoclax therapy in AML. Blood. American Society of Hematology; 2025. p. 1660–1660.